HDFC Bank Limited Common Stock vs Sanofi SA — how do they compare? HDFC Bank Limited Common Stock trades at $22 (market cap $112.43B), while Sanofi SA trades at $40.22 (market cap $96.81B). The key difference: HDFC Bank Limited Common Stock is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold HDFC Bank Limited Common Stock for 0 Days and Sanofi SA for 94 Days on average.
| HDB | SNY | |
|---|---|---|
Market Cap | $112.43B | $96.81B |
Volume | 7,511,454 | 2,081,815 |
Sector | Financials | Health |
52-Week High | $37.18 | $52.34 |
52-Week Low | $21.84 | $39.51 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $13.95T | $116.20B |
Dividend Yield | 1.85% | 6.02% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
HDFC Bank provides retail, wholesale, and treasury banking services in India. Its offerings include deposits, lending, payments, trade finance, and financial services for individuals and businesses.
Read more on HDB →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →